MAPT and Alzheimer disease: [14] Specifically, these nanoparticulate systems effectively differentiated between healthy controls and AD patients and showed a 6‐fold increase in total‐tau levels and a threefold increase in phosphorylated‐tau levels between AD patients and the healthy controls.